Denovo Biopharma In-licenses Cancer Drug from Lilly

Denovo Biopharma, a US-China biopharma, acquired global rights to enzastaurin, a late-clinical-stage oncology drug from Eli Lilly. In 2013, enzastaurin failed a Phase III clinical trial for diffuse large B-cell lymphoma, though it significantly improved progression-free survival in a subset of patients. Denovo believes it can use its proprietary biomarker expertise to identify that patient group and conduct a successful trial of enzastaurin. Denovo is headquartered in San Diego with a lab in Hangzhou. More details... Stock Symbol: (NYSE: LLY) Share this with colleagues: // //